ATL-101

N/A

Report date: 2025/10/20 14:43:46

Base Information

Drug NameATL-101
Drug Alias NameAnti-PSMA monoclonal antibody J591Lutetium-177-labelled anti-PSMA monoclonal antibody J591Lu-177-J591177Lu-J591muJ-591 +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionIonising radiation emittersAnti-PSMA
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsKidney NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesWeill Medical College of Cornell University
China Registration ClassN/A

Develop Information

Active CompaniesWeill Medical College of Cornell University
Inactive CompaniesBzl Biologics IncNational Cancer InstituteMillennium Pharmaceuticals Inc
Active IndicationsKidney NeoplasmsProstatic NeoplasmsCarcinoma, Non-Small-Cell Lung +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A